Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods: Using data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab. Results: The study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response. Conclusions: Our study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.
Abstract
Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods: Using data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab. Results: The study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response. Conclusions: Our study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.
참고문헌 (52)
- Singal AG, "Global trends in hepatocellular carcinoma epidemiology : implications for screening, prevention and therapy", Nat Rev Clin Oncol, 20, pp.864~884 (2023)
- Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Siegel RL, "Cancer statistics, 2024", CA Cancer J Clin, 74, pp.12~49 (2024)
- Rumgay H, "Global burden of primary liver cancer in 2020 and predictions to 2040", J Hepatol, 77, pp.1598~1606 (2022)
- Chan LL, "The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment", Clin Mol Hepatol, 29, pp.909~923 (2023)
- Korman AJ, "The foundations of immune checkpoint blockade and the ipilimumab approval decennial", Nat Rev Drug Discov, 21, pp.509~528 (2022)
- Llovet JM, "Immunotherapies for hepatocellular carcinoma", Nat Rev Clin Oncol, 19, pp.151~172 (2022)
- Sankar K, "Recent advances in the management of hepatocellular carcinoma", Clin Mol Hepatol, 30, pp.1~15 (2024)
- Sangro B, "Advances in immunotherapy for hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 18, pp.525~543 (2021)
- Lonberg N, "Masterful antibodies : checkpoint blockade", Cancer Immunol Res, 5, pp.275~281 (2017)
- Sharma P, "The next decade of immune checkpoint therapy", Cancer Discov, 11, pp.838~857 (2021)
- Sangro B, "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C", J Hepatol, 59, pp.81~88 (2013)
- El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
- Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
- Qin S, "RATIONALE 301 study : tislelizumab versus sorafenib as firstline treatment for unresectable hepatocellular carcinoma", Future Oncol, 15, pp.1811~1822 (2019)
- Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
- Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
- Cheng AL, "Updated efficacy and safety data from IMbrave150 : atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma", J Hepatol, 76, pp.862~873 (2022)
- Zhu AX, "Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma", Nat Med, 28, pp.1599~1611 (2022)
- Sogbe M, "Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment", Clin Mol Hepatol, 30, pp.177~190 (2024)
- Ock CY, "Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers", Nat Commun, 8, pp.1050~ (2017)
- Lee MS, "Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140) : an open-label, multicentre, phase 1b study", Lancet Oncol, 21, pp.808~820 (2020)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Hsu CL, "Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma", Liver Cancer, 10, pp.346~359 (2021)
- Cancer Genome Atlas Research Network, "Comprehensive and integrative genomic characterization of hepatocellular carcinoma", Cell, 169, pp.1327~1341 (2017)
- Sohn BH, "Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project", Clin Cancer Res, 23, pp.4441~4449 (2017)
- Oh SC, "Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype", Nat Commun, 9, pp.1777~ (2018)
- Jung J, "Clinical significance of glycolytic metabolic activity in hepatocellular carcinoma", Cancers(Basel), 15, pp.186~ (2022)
- Lee SH, "Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials", Cancer Commun(Lond), 42, pp.179~183 (2022)
- Lee SH, "Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes", Hepatology, 76, pp.1634~1648 (2022)
- Jeong YS, "Clinically conserved genomic subtypes of gastric adenocarcinoma", Mol Cancer, 22, pp.147~ (2023)
- Simon R, "Analysis of gene expression data using BRB-ArrayTools", Cancer Inform, 3, pp.11~17 (2007)
- Eisen MB, "Cluster analysis and display of genome-wide expression patterns", Proc Natl Acad Sci U S A, 95, pp.14863~14868 (1998)
- Lee JS, "Application of comparative functional genomics to identify best-fit mouse models to study human cancer", Nat Genet, 36, pp.1306~1311 (2004)
- Lee JS, "Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling", Hepatology, 40, pp.667~676 (2004)
- Lee JS, "A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells", Nat Med, 12, pp.410~416 (2006)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Tibshirani R, "Diagnosis of multiple cancer types by shrunken centroids of gene expression", Proc Natl Acad Sci U S A, 99, pp.6567~6572 (2002)
- Newman AM, "Robust enumeration of cell subsets from tissue expression profiles", Nat Methods, 12, pp.453~457 (2015)
- Thorsson V, "The immune landscape of cancer", Immunity, 48, pp.812~830 (2018)
- Sanchez-Vega F, "Oncogenic signaling pathways in the cancer genome atlas", Cell, 173, pp.321~337 (2018)
- Bailey MH, "Comprehensive characterization of cancer driver genes and mutations", Cell, 173, pp.371~385 (2018)
- Liu J, "An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics", Cell, 173, pp.400~416 (2018)
- Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
- Huang CF, "Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era : Correspondence to editorial on"Unmet needs in the post-direct-acting antivirals era : The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication"", Clin Mol Hepatol, 30, pp.1023~1025 (2024)
- Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib : the CheckMate 040 randomized clinical trial", JAMA Oncol, 6, pp.e204564~ (2020)
- Galle PR, "Nivolumab(NIVO)plus ipilimumab(IPI)vs lenvatinib(LEN)or sorafenib(SOR)as first-line treatment for unresectable hepatocellular carcinoma(uHCC) : First results from CheckMate 9DW", J Clin Oncol, 42, pp.suppl 17;LBA4008.~ (2024)
- Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC", Nature, 592, pp.450~456 (2021)
- Wu YL, "Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors", BJC Reports, 2, pp.8~ (2024)
- Meyer T, "Aetiology of liver disease and response to immune checkpoint inhibitors : An updated meta-analysis confirms benefit in those with non-viral liver disease", J Hepatol, 79, pp.e73~e76 (2023)
- Hatanaka T, "Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection : a Japanese multicenter observational study", Cancer Med, 12, pp.5293~5303 (2023)
- Llovet JM, "Nonalcoholic steatohepatitisrelated hepatocellular carcinoma : pathogenesis and treatment", Nat Rev Gastroenterol Hepatol, 20, pp.487~503 (2023)